Drugs / LYN101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07178327 | Sep 2025 → Sep 2026 overdue | osteoporosis | Shanghai TTM-Bio Technology Co., Ltd | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYN101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07178327 ↗ |
| Route | Subcutaneous | “administered as a subcutaneous (SC) injection.” NCT07178327 ↗ |